Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Studies have shown that women on the Alzheimer's disease (AD) continuum have more pathological tau in the brain and cerebrospinal fluid (CSF), than men.
Why it matters
This study examined whether sex differences apply to plasma p-tau181 in relation to Alzheimer's disease biomarkers, cognitive decline and clinical progression. It is observational and does not provide a treatment or cure.
-
Alzheimer's disease is the most common form of dementia and the fifth-leading cause of death among people over the age of 65.
Why it matters
This study used a pre-trained CNN model to automatically extract features from MRI images for diagnosing Alzheimer's disease, then evaluated classification with Softmax, SVM, and random forest. The model achieved accuracy ranging from 85.7% to 99% on the ADNI dataset.
-
The two groups' baseline characteristics, including age, sex, mean length of education, and disease duration, were comparable, as were their baseline Mini-Mental State Examination scores.
Why it matters
In this six-month trial of 85 people with moderate Alzheimer's disease, behavioral and psychological symptom scores improved from baseline in both the donepezil and memantine groups. The authors conclude these drugs may be effective for such symptoms with a favorable safety profile, though this addresses symptom relief rather than curing the disease.
-
Alzheimer's disease (AD) is a major contributor of dementia leading to the degeneration of neurons in the brain with major symptoms like loss of memory and learning.
Why it matters
This review reports that neuroinflammation is involved in Alzheimer's pathology, with cytokines such as TNF-alpha and IL-6 increasing BACE1 activity and NF-kB expression that lead to amyloid-beta generation. It discusses pathways as possible therapeutic targets but reports no demonstrated treatment or prevention in patients.
-
We established AD diagnostic models using plasma biomarkers for Chinese participants.
Why it matters
In a Chinese population, among all blood biomarkers p-tau181 had the greatest potential for identifying patients with cognitive impairment, and a simplified model combining plasma p-tau181, Aβ42, and clinical features achieved 93.3% area under the curve, 78.6% sensitivity, and 94.2% specificity for distinguishing Alzheimer disease from controls. The authors suggest this simplified diagnostic model provides an accessible and practical way for large-scale screening, but it concerns diagnosis rather than treatment, cure, or prevention.
-
Identifying biomarkers associated with Alzheimer's disease (AD) progression may enable patient enrichment and improve clinical trial designs.
Why it matters
This study looked at peripheral blood DNA methylation profiles in Alzheimer's Disease Neuroimaging Initiative participants to see if they were related to Alzheimer's disease progression. The rate of cognitive decline was estimated from the initial DNA sampling visit to subsequent visits, and correlations with methylation at specific sites were examined.
-
Alzheimer disease (AD) is the most common cause of dementia in older individuals (>65 years) and has a long presymptomatic phase.
Why it matters
This review argues for low-level inhibition of BACE1 as a possible way to prevent Alzheimer's disease by reducing amyloid-beta production. However, it notes that all phase II and phase III clinical trials of BACE inhibitors to date have failed, so no preventive therapy is yet available.
-
Alzheimer's disease (AD) is a complex neurodegenerative disease in the elderly and the most common cause of human dementia.
Why it matters
This review describes autophagy as a lysosome-dependent cellular process linked to protein metabolism, and notes that Alzheimer's disease involves accumulation of amyloid plaques and hyper-phosphorylated tau tangles. It discusses autophagy as a potential therapeutic direction but reports no demonstrated treatment, cure or prevention.
-
Magnetic resonance spectroscopy detects Alzheimer's disease related inflammation and neurodegeneration, and could be a good noninvasive disease-stage biomarker in Down syndrome.
Why it matters
In adults with Down syndrome, a marker of neuroinflammation was elevated even before symptoms and rose with disease progression, while a marker of neuronal integrity changed mainly at symptomatic stages. This is about tracking disease processes with imaging and biomarkers, not about treating, curing, or preventing Alzheimer's.
-
Twenty-seven individuals (14%) had an abnormal amyloid PET, and 14 twin-pairs (15%) showed discordant amyloid PET scans.
Why it matters
In 96 identical twin pairs, amyloid and tau markers were strongly correlated within pairs, suggesting a substantial genetic or shared environmental contribution to these changes. The authors suggest that modifying environmental risk factors might delay disease processes, but the study did not test any treatment, cure, or prevention.
-
Previous research has described distinct subtypes of Alzheimer's disease (AD) based on the differences in regional patterns of brain atrophy on MRI.
Why it matters
This study used FDG-PET data and clustering to identify distinct hypometabolic subtypes of Alzheimer's disease-related neurodegeneration. It describes subtypes of brain metabolism, not a treatment, cure or prevention.
-
Mild cognitive impairment (MCI) detection using magnetic resonance image (MRI), plays a crucial role in the treatment of dementia disease at an early stage.
Why it matters
This work uses a deep learning method with transfer learning and brain tissue segmentation to help diagnose early-stage Alzheimer's disease on MRI images. It is a diagnostic tool only and does not test any treatment, cure, or prevention.
-
Alzheimer's disease is the leading cause of dementia.
Why it matters
This study used machine learning on retinal images from the UK Biobank to classify Alzheimer's disease with an average accuracy of 82.44%, and found that small blood vessels in the retina carry more information for diagnosis. It is about using eye images for diagnosis, not about treating, curing or preventing Alzheimer's disease.
-
We show that m 6 A modification displays temporal and spatial dynamics during neurodevelopment and aging.
Why it matters
This study describes how m6A RNA modification changes during brain development and aging and notes a potential role in Alzheimer's disease. It is basic biology and does not test any treatment, cure or prevention.
-
The projected burden of dementia by Alzheimer's disease (AD) represents a looming healthcare crisis as the population of most countries grows older.
Why it matters
This study trained deep learning models on structural MRI brain images to classify them into Alzheimer's disease, mild cognitive impairment, and cognitively normal groups. One configuration of the method reached 52.3% accuracy on the CADDementia challenge.
-
The dynamics of the resting brain exhibit transitions between a small number of discrete networks, each remaining stable for tens to hundreds of milliseconds.
Why it matters
EEG microstate complexity was altered in Alzheimer's disease, with slower and less complex microstate transitioning, and combined with a spectral measure it classified Alzheimer's with sensitivity and specificity above 80%. It could predict progression from mild cognitive impairment to Alzheimer's in a small preliminary cohort of 11 participants, so this is early work.
-
We developed and validated a novel Simoa immunoassay to detect p-tau T217 in CSF.
Why it matters
This study developed and validated a new immunoassay for p-tau Thr217 in cerebrospinal fluid and tested whether it could distinguish Alzheimer's disease from other dementias and healthy controls. It is a diagnostic test study, not a treatment, cure, or prevention for Alzheimer's disease.
-
Since the world population is ageing, dementia is going to be a growing concern.
Why it matters
Re-analysing gene activity from three studies of the Alzheimer's hippocampus, researchers found only one consistent pathway, calcium signalling, made up of 48 genes that were turned down. They predicted and confirmed in lab-grown HEK cells that a small regulatory molecule, miR-129, controls six of these genes, and found it raised in rats with drug-induced memory loss. This is early lab work, pointing to miR-129 as a candidate for further study in synapse function and Alzheimer's rather than a treatment.
-
Alzheimer's disease (AD) is the most common form of neurodegenerative disorder with dementia, accounting for approximately 70% of the all cases.
Why it matters
This review describes the GSK3-β signaling pathway as involved in tau phosphorylation, amyloid-β production, memory, neurogenesis and synaptic function, and discusses it as a possible drug target. It reports that there is currently no cure and that GSK3-β inhibitors are still being studied in preclinical and clinical research.
-
The current study examined the interactive effect of type 2 diabetes and Alzheimer disease (AD) risk factors on the rate of functional decline in cognitively normal participants from the Alzheimer's Disease Neuroimaging Initiative.
Why it matters
In cognitively normal participants from the Alzheimer's Disease Neuroimaging Initiative, this study examined whether type 2 diabetes interacts with Alzheimer disease risk factors to predict five-year change in everyday functioning. It concerns prediction of functional decline and does not test any treatment or prevention.
-
Chain-free SFA and TFA occur in greater amounts in the brains of individuals with AD than in those without AD.
Why it matters
Pooling 19 randomised trials with 2297 patients, this meta-analysis reports that certain saturated and trans fatty acids were found at higher levels in the brains of people with Alzheimer's than in controls. It also reports that a year of the B vitamins folate, cobalamin and pyridoxine lowered plasma tHcy levels and brain atrophy, and that Souvenaid helped synapse formation. Overall it points to diet-related factors worth further study rather than a proven nutritional treatment.
-
In recent years, several high-dimensional, accurate, and effective classification methods have been proposed for the automatic discrimination of the subject between Alzheimer's disease (AD) or its prodromal phase {i.e., mild cognitive impairment (MCI)} and healthy control (HC) persons based on T1-weighted structural magnetic resonance imaging (sMRI).
Why it matters
This is a technical study proposing a new computer method to classify brain MRI scans as Alzheimer's, mild cognitive impairment, or healthy. It is a diagnostic tool for research and does not test any treatment, cure, or prevention.
-
A gradient boosted machine (GBM) predicted the presence of AD as a function of gender, age, education, socioeconomic status (SES), and a mini-mental state exam (MMSE).
Why it matters
Machine learning methods classified Alzheimer's disease with high accuracy using socio-demographic, clinical and MRI data, with the MMSE being the most important feature. This is about improving detection and diagnosis, not about treating, curing or preventing the disease.
-
Patients with AD and MCI have decreased microbial diversity, and changes in gut microbiota could be detected for early detection of AD.
Why it matters
This early study found that people with mild cognitive impairment and people with Alzheimer's disease had similar changes in gut bacteria, and a model using fecal samples correctly identified 93% of the MCI patients. The authors note that diagnosis was based only on symptoms and neuroimaging, so further studies with Alzheimer's biomarkers are needed before this could be used to detect the disease early.
-
The final algorithm demonstrated an AUROC of 0.88, sensitivity of 77.7%, and a specificity of 79.9% on excluded test data.
Why it matters
This study developed a machine learning algorithm using easily obtained clinical information to predict conversion from mild cognitive impairment to Alzheimer's disease. The authors suggest it could help improve recruitment in clinical trials and more selectively prescribe early interventions to high-risk patients, but it does not itself test a treatment, cure or prevention.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer's disease progression and heterogeneity
- Risk of dementia among white and African American relatives of patients with Alzheimer disease
- Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease
- Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging
- Longitudinal Association of Total Tau Concentrations and Physical Activity With Cognitive Decline in a Population Sample
- Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients
- Risk Factors and Pathological Substrates Associated with Agitation/Aggression in Alzheimer's Disease: A Preliminary Study using NACC Data
- CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings
- Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015–2060) in adults aged ≥65 years
- Use of an Alzheimer's disease polygenic risk score to identify mild cognitive impairment in adults in their 50s